Look at Madrigal's move from $74 to $98 in the 5 days since revealing the phase III data that will be released in an oral presentation at a major liver conference on Nov 12.
Oral presentation means significant news. Companies don't apply for an oral presentation at a major conference unless the news is positive.
Viking will move with Madrigal news as it always has done.
Time to buy back shares. The big data releases coming over the next few weeks are likely to verify the impressive date discussed int the liver conference.
Biomarkers continue to correlate with disease state and with treatment response. Expecting 30% of responders to completely reverse NASH. Safety of beta/liver focused thyroid drug is looking safer than the thyroid treatments ten of millions in US take daily. Thyroid supplements now have a 100 year safety record.
News 
Market Data 
Discover 
